GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Energenesis Biomedical Co Ltd (TPE:6657) » Definitions » Net Income Including Noncontrolling Interests

Energenesis Biomedical Co (TPE:6657) Net Income Including Noncontrolling Interests : NT$-285.26 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Energenesis Biomedical Co Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Energenesis Biomedical Co's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was NT$-96.97 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-285.26 Mil.


Energenesis Biomedical Co Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Energenesis Biomedical Co's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Energenesis Biomedical Co Net Income Including Noncontrolling Interests Chart

Energenesis Biomedical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -129.48 -120.24 -265.66 -260.38 -231.08

Energenesis Biomedical Co Quarterly Data
Jun19 Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.79 -48.72 -89.68 -49.89 -96.97

Energenesis Biomedical Co Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-285.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Energenesis Biomedical Co Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Energenesis Biomedical Co's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Energenesis Biomedical Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. It is engaged in businesses related to biological experimentation and analysis, as well as new drug development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. Its product pipeline consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream, among others.

Energenesis Biomedical Co Headlines

No Headlines